QQ客服 官方微博 反馈留言

	Safety, Pharmacokinetics and Dosimetry of a Long-lasting Radiolabeled Somatostatin Analogue Lu-177-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors: A Phase 1 First-in-human Study
	Zhang, Jingjing; Niu, Gang; Wang, Hao; Jacobson, Orit; Cheng, Yuejuan; Zang, Jie; Li, Fang; Bai, Chunmei; Zhu, Zhaohui; Chen, Xiaoyuan
	2018
卷号	59
ISSN号	0161-5505
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6347153
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Zhang, Jingjing,Niu, Gang,Wang, Hao,et al. Safety, Pharmacokinetics and Dosimetry of a Long-lasting Radiolabeled Somatostatin Analogue Lu-177-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors: A Phase 1 First-in-human Study[J],2018,59.
APA	Zhang, Jingjing.,Niu, Gang.,Wang, Hao.,Jacobson, Orit.,Cheng, Yuejuan.,...&Chen, Xiaoyuan.(2018).Safety, Pharmacokinetics and Dosimetry of a Long-lasting Radiolabeled Somatostatin Analogue Lu-177-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors: A Phase 1 First-in-human Study.,59.
MLA	Zhang, Jingjing,et al."Safety, Pharmacokinetics and Dosimetry of a Long-lasting Radiolabeled Somatostatin Analogue Lu-177-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors: A Phase 1 First-in-human Study".59(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。